PTC Therapeutics (PTCT) Director Schmertzler Sells $671K of Stock
Key Points
- Director Michael Schmertzler sold 10,000 shares of PTC Therapeutics, Inc. (NasdaqGS: PTCT) at a price of $67.12 per share on September 16, 2026, in a pre-arranged transaction.
- The stock recently traded around $59.22 as of October 16, 2026, sitting below its 50-day moving average of $67.72 and heading toward its next earnings report on October 29, 2026.
- Other institutional investors and insiders have adjusted their holdings recently, while analysts maintain an average price target of $100.33 for the biotech firm.
Since the trade, $PTCT is down 7.8% after 1 week, down 12.3% after 1 month and down 10.8% to date (from the $67.59 close on Sep 16, 2026).
Get PTC Therapeutics text alerts
We text you when insiders, Congress, analysts or big funds move on $PTCT.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated PTC Therapeutics, Inc. alert may contain errors. Disclosures
Director Michael Schmertzler of PTC Therapeutics, Inc. (NasdaqGS: PTCT) sold 10,000 shares of the biotechnology company on September 16, 2026. The transaction was revealed in a Form 4 filing submitted to the Securities and Exchange Commission.
PTCT
PTC Therapeutics, Inc.
Inside Michael Schmertzler's PTCT Trade
Schmertzler parted with the shares at a price of $67.12 each, bringing the total value of the sale to $671,195. The stock closed at $67.59 on the day of the trade. According to the regulatory filing, the sale was carried out under a pre-arranged trading plan.
Other Institutional Activity in PTC Therapeutics
Institutional investors have been shifting their positions in the firm recently. Burney Co. sold its entire stake, dropping 37,320 shares to end with zero holdings valued at $0. Meanwhile, Jupiter Topco LLC grew its holdings by 3,618,201 shares, ending with 7,236,402 shares worth about $428,684,466. RTW Investments LP kept its stake steady at 7,746,415 shares valued at $458,897,637.
PTC Therapeutics, Inc. Stock Down 2.9%
The stock recently traded around $59.22 as of October 16, 2026, down about 12.4% from its close on the day of Schmertzler's trade. The shares sit below both the 50-day moving average of $67.72 and the 200-day moving average of $71.49. The company has a market cap of roughly $4.94 billion and trades well below its 52-week high of $90.87.
Recent Earnings
For the trailing twelve months, the company reported revenue of $1,008,753,984 with a net margin of -3.8% and an earnings per share of -0.62. Revenue grew 101.5% year-over-year. The next earnings release is scheduled for October 29, 2026.
Insider Buying and Selling at PTC Therapeutics, Inc.
Other executives have also executed trades in recent months, including Chief Technical Ops Officer Neil Gregory Almstead, who completed both purchases and planned sales earlier in the year.
Analysts Set New Price Targets
Wall Street firms maintain coverage on the stock with Wells Fargo, Morgan Stanley, and Barclays holding Overweight ratings and price targets ranging from $93 to $122. The consensus recommendation stands at a buy with a mean price target of $100.33.
About PTC Therapeutics
Headquartered in Warren, New Jersey, PTC Therapeutics, Inc. discovers, develops, and distributes medicines for children and adults facing rare disorders.
Bottom Line
Investors will watch for the company's upcoming earnings report scheduled for October 29, 2026, for further updates on financial performance and pipeline progress.
Related Filing Alerts
Source: Michael Schmertzler's Form 4 filing on $PTCT (Sep 16, 2026). Written by software, not financial advice. How we make alerts